The Amount of Activating EGFR Mutations in Circulating Cell-Free DNA Is a Marker to Monitor Osimertinib Response
British Journal of Cancer - United Kingdom
doi 10.1038/s41416-018-0238-z
Full Text
Open PDFAbstract
Available in full text
Date
November 1, 2018
Authors
Publisher
Springer Science and Business Media LLC